Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study
Hughes SE. et al, (2025), Eclinicalmedicine, 84
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).
Chakraverty R. et al, (2025), BMJ Open, 15
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies.
Khatsuria F. et al, (2024), Lancet Oncol, 25, e476 - e488
Integrating patient and public involvement and engagement in translational medicine.
Shaw KL. et al, (2024), Lancet, 404, 828 - 831
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?
Chakraverty R., (2024), J Clin Oncol
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588
The road to refractory graft-versus-host disease is paved with good intentions
North D. and Chakraverty R., (2024), Journal of Clinical Investigation, 134
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.
Cheminant M. et al, (2022), Blood
CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy
Gu Y. et al, (2022), Practical Transfusion Medicine: Sixth Edition, 543 - 553
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
Sweeney C. et al, (2022), BLOOD, 140, 1576 - 1578
Graft-versus-host disease: a disorder of tissue regeneration and repair.
Chakraverty R. and Teshima T., (2021), Blood
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Marzolini MAV. et al, (2021), Transplant Cell Ther, 27, 682.e1 - 682.e12
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
Zeiser R. et al, (2021), New England Journal of Medicine, 385, 228 - 238
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Schetelig J. et al, (2021), Bone Marrow Transplant, 56, 605 - 613
Graft Versus Leukemia: Current Status and Future Perspectives.
O'Neill AT. and Chakraverty R., (2021), J Clin Oncol, 39, 361 - 372
Allogeneic HSCT For Adolescents and Adults With Inborn Errors of Immunity: A Retrospective Study of The Inborn Errors Working Party (IEWP)
Albert M. et al, (2021), BONE MARROW TRANSPLANTATION, 56, 101 - 102
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (Bone Marrow Transplantation, (2021), 56, 3, (605-613), 10.1038/s41409-020-01069-w)
Schetelig J. et al, (2021), Bone Marrow Transplantation
Phenotype Reversal, Excellent Overall, GVHD-free And Graft Failure-Free Survival In 55 Adolescents And Adults With Inborn Errors of Immunity Following Reduced Intensity Allogeneic HSCT
Fox TA. et al, (2021), BONE MARROW TRANSPLANTATION, 56, 103 - 105